AU2013286680B2 - Antibodies to tau - Google Patents

Antibodies to tau Download PDF

Info

Publication number
AU2013286680B2
AU2013286680B2 AU2013286680A AU2013286680A AU2013286680B2 AU 2013286680 B2 AU2013286680 B2 AU 2013286680B2 AU 2013286680 A AU2013286680 A AU 2013286680A AU 2013286680 A AU2013286680 A AU 2013286680A AU 2013286680 B2 AU2013286680 B2 AU 2013286680B2
Authority
AU
Australia
Prior art keywords
pct
tau
antibody
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013286680A
Other languages
English (en)
Other versions
AU2013286680A1 (en
Inventor
Marc Diamond
Brandon HOLMES
David Holtzman
Hong Jiang
Najla KFOURY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of AU2013286680A1 publication Critical patent/AU2013286680A1/en
Application granted granted Critical
Publication of AU2013286680B2 publication Critical patent/AU2013286680B2/en
Priority to AU2018229564A priority Critical patent/AU2018229564A1/en
Priority to AU2020223765A priority patent/AU2020223765A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
AU2013286680A 2012-07-03 2013-07-03 Antibodies to tau Active AU2013286680B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018229564A AU2018229564A1 (en) 2012-07-03 2018-09-17 Antibodies to tau
AU2020223765A AU2020223765A1 (en) 2012-07-03 2020-08-28 Antibodies to tau

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30
PCT/US2013/049333 WO2014008404A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018229564A Division AU2018229564A1 (en) 2012-07-03 2018-09-17 Antibodies to tau

Publications (2)

Publication Number Publication Date
AU2013286680A1 AU2013286680A1 (en) 2015-01-22
AU2013286680B2 true AU2013286680B2 (en) 2018-07-05

Family

ID=49882495

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013286680A Active AU2013286680B2 (en) 2012-07-03 2013-07-03 Antibodies to tau
AU2018229564A Abandoned AU2018229564A1 (en) 2012-07-03 2018-09-17 Antibodies to tau
AU2020223765A Abandoned AU2020223765A1 (en) 2012-07-03 2020-08-28 Antibodies to tau

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018229564A Abandoned AU2018229564A1 (en) 2012-07-03 2018-09-17 Antibodies to tau
AU2020223765A Abandoned AU2020223765A1 (en) 2012-07-03 2020-08-28 Antibodies to tau

Country Status (17)

Country Link
US (2) US9834596B2 (OSRAM)
EP (2) EP2870176A4 (OSRAM)
JP (3) JP6345655B2 (OSRAM)
KR (3) KR20200013072A (OSRAM)
CN (2) CN108623682A (OSRAM)
AU (3) AU2013286680B2 (OSRAM)
BR (1) BR112014033116B1 (OSRAM)
CA (1) CA2877397A1 (OSRAM)
HK (1) HK1209768A1 (OSRAM)
IL (3) IL236409B (OSRAM)
IN (1) IN2015KN00007A (OSRAM)
MX (2) MX359555B (OSRAM)
MY (1) MY171473A (OSRAM)
NZ (2) NZ739622A (OSRAM)
RU (2) RU2018132044A (OSRAM)
SG (3) SG10201913370PA (OSRAM)
WO (1) WO2014008404A1 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014033116B1 (pt) 2012-07-03 2021-12-21 Washington University Anticorpo anti-tau monoclonal isolado
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA2952745A1 (en) * 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
TWI790642B (zh) 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法
PH12017502207B1 (en) * 2015-07-06 2022-08-10 UCB Biopharma SRL Tau-binding antibodies
JP6937289B2 (ja) 2015-07-06 2021-09-22 ユーシービー バイオファルマ エスアールエル Ｔａｕ結合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN108137679B (zh) * 2015-08-13 2022-07-19 纽约大学 对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
CN109580954B (zh) * 2015-09-16 2022-03-22 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
UA124104C2 (uk) 2016-07-12 2021-07-21 Х. Луннбек А/С Антитіла, специфічні до гіперфосфорилованого тау-білка, і способи їх застосування
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
CA3044679A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
US11078272B2 (en) * 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
CU24636B1 (es) 2017-05-02 2022-12-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
KR102225178B1 (ko) * 2017-10-16 2021-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
CA3094934A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
WO2019207164A1 (en) * 2018-04-27 2019-10-31 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2020190927A1 (en) * 2019-03-18 2020-09-24 Regeneron Pharmaceuticals, Inc. Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
EP4317950A3 (en) 2019-03-18 2024-04-17 Regeneron Pharmaceuticals, Inc. Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
PH12022550106A1 (en) * 2019-07-15 2022-11-21 Adel Inc Anti-tau antibody and use thereof
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
JP2022551478A (ja) 2019-10-09 2022-12-09 ブルーロック セラピューティクス エルピー 持続的トランスジーン発現を伴う細胞
WO2021110995A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
US20220145363A1 (en) * 2020-11-09 2022-05-12 Meso Scale Technologies, Llc. Methods and kits for detecting tau
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
MX2023011339A (es) 2021-03-26 2023-12-14 Janssen Biotech Inc Anticuerpos anti-tau y usos de estos.
IL307168A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Humanized antibodies against paired helical strands of TAU protein and their uses
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
IL318722A (en) * 2022-08-23 2025-03-01 Washington University St Louis Anti-tau MTBR antibodies and methods for detecting cleaved tau fragments and uses thereof
WO2025018933A1 (en) * 2023-07-20 2025-01-23 Montoliu Gaya Laia P-tau immunoassay

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316564A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO884368L (no) 1987-10-02 1989-04-03 Du Pont Immunanalyse ved anvendelse av igg-innfangelsesantistoff og multippel, monoklonalt antistoffpaavisningssystem.
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
WO1993008302A1 (en) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
EP0618968B1 (en) 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
ATE234324T1 (de) 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
CN101046476B (zh) 1998-09-08 2013-04-10 基因创新有限公司 特异性识别τ的抗体的用途,及包含该抗体的试剂盒
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
SI2371392T1 (sl) 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
AU2005327652A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
US20070134724A1 (en) 2005-08-04 2007-06-14 Peter Davies Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CN104666297A (zh) 2008-04-24 2015-06-03 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
CN102292078A (zh) * 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
RU2518291C2 (ru) * 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
CA2772379C (en) 2009-08-28 2019-09-24 Rakez Kayed Antibodies that bind tau oligomers
ES2687469T3 (es) * 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Marcadores autoanticuerpos para el diagnóstico de traumatismo craneoencefálico
BR112012008381A2 (pt) 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) interação fkbp52-tau como novo alvo terapêutico para tratar os distúrbios neurológicos envolvendo disfunção da tau
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
EP2987807A3 (en) 2010-10-07 2016-06-01 AC Immune S.A. Antibodies recognising phospho-tau
HRP20181320T8 (hr) * 2010-10-11 2018-12-14 Biogen International Neuroscience Gmbh Ljudska anti-tau protutijela
EP2670434B1 (en) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
JP6457263B2 (ja) 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
SG10201703771WA (en) 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
MX380302B (es) 2011-12-20 2025-03-12 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
US20150183854A1 (en) 2012-05-31 2015-07-02 Teijin Pharma Limited Therapeutic agent or prophylactic agent for dementia
BR112014033116B1 (pt) 2012-07-03 2021-12-21 Washington University Anticorpo anti-tau monoclonal isolado
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
AU2013305848B2 (en) 2012-08-21 2020-10-15 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
AU2013328881B2 (en) 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
ES2816700T3 (es) 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316564A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Also Published As

Publication number Publication date
AU2020223765A1 (en) 2020-09-17
KR20150036346A (ko) 2015-04-07
KR20200013072A (ko) 2020-02-05
NZ703423A (en) 2018-02-23
BR112014033116A2 (pt) 2018-03-06
WO2014008404A1 (en) 2014-01-09
US20180037641A1 (en) 2018-02-08
CN104781278A (zh) 2015-07-15
MX2022000026A (es) 2022-03-22
JP2015530971A (ja) 2015-10-29
MX359555B (es) 2018-10-02
AU2018229564A1 (en) 2018-10-04
AU2013286680A1 (en) 2015-01-22
IL236409A0 (en) 2015-02-26
EP3838921A3 (en) 2021-09-01
JP6345655B2 (ja) 2018-06-20
EP2870176A1 (en) 2015-05-13
US20150183855A1 (en) 2015-07-02
US9834596B2 (en) 2017-12-05
KR20200134339A (ko) 2020-12-01
IL277643A (en) 2020-11-30
EP2870176A4 (en) 2016-09-28
RU2018132044A (ru) 2018-10-19
BR112014033116B1 (pt) 2021-12-21
HK1209768A1 (en) 2016-04-08
MY171473A (en) 2019-10-15
EP3838921A2 (en) 2021-06-23
RU2015103228A (ru) 2016-08-20
SG11201408626YA (en) 2015-03-30
RU2015103228A3 (OSRAM) 2018-03-05
IL236409B (en) 2020-10-29
IN2015KN00007A (OSRAM) 2015-07-31
CA2877397A1 (en) 2014-01-09
IL289241A (en) 2022-02-01
NZ739622A (en) 2020-01-31
JP2020125310A (ja) 2020-08-20
SG10201708959WA (en) 2017-11-29
CN104781278B (zh) 2018-06-12
KR102494798B1 (ko) 2023-02-06
RU2668159C2 (ru) 2018-09-26
SG10201913370PA (en) 2020-03-30
MX2014016024A (es) 2015-04-13
CN108623682A (zh) 2018-10-09
JP2018184398A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2013286680B2 (en) Antibodies to tau
JP6878395B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
EP2074145B1 (en) Humanized antibody against amyloid beta
JP6124591B2 (ja) タウオリゴマーに結合する抗体
AU2017295608A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
HRP20090221A2 (hr) Humanizirano protutijelo
TW201441256A (zh) 抗β類澱粉蛋白單株抗體
US20210122810A1 (en) Binding molecules that specifically bind to tau
JP7144755B2 (ja) 薬剤、使用および方法
CN113651887A (zh) 人源抗亨廷顿蛋白（htt）抗体及其用途
JP2020511963A (ja) ヒトアルファ−シヌクレインに対する抗体
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
CN118369329A (zh) 治疗神经退行性疾病的方法和物质
US11274147B2 (en) Binding molecules that specifically bind to tau
HK40055622A (en) Antibodies to tau
AU2013202799C1 (en) Humanized antibody against amyloid beta
US20240352102A1 (en) Compositions for treating tauopathies and methods of use thereof
CN120584130A (zh) 用纳米抗体靶向gpr158(mglyr)用于治疗益处
KR20250027500A (ko) 청각 장애 치료를 위한 항-fam19a5 길항제의 용도
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)